Data Collective IV’s Recursion Pharmaceuticals RXRX Stock Holding History

Data Collective IV’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.8M	Hold	5,941,120	–	–	27.76%	3
2026 Q1	$18.2M	Hold	5,941,120	–	–	32.6%	2
2025 Q4	$24.3M	Hold	5,941,120	–	–	41.53%	2
2025 Q3	$29M	Hold	5,941,120	–	–	42.65%	2
2025 Q2	$30.1M	Hold	5,941,120	–	–	23.14%	3
2025 Q1	$31.4M	Hold	5,941,120	–	–	36.17%	1
2024 Q4	$40.2M	Hold	5,941,120	–	–	17.75%	2
2024 Q3	$39.2M	Hold	5,941,120	–	–	23.95%	3
2024 Q2	$44.6M	Hold	5,941,120	–	–	31.23%	2
2024 Q1	$59.2M	Hold	5,941,120	–	–	51.36%	1
2023 Q4	$58.6M	Hold	5,941,120	–	–	48.46%	1
2023 Q3	$45.4M	Hold	5,941,120	–	–	43%	2
2023 Q2	$44.4M	Hold	5,941,120	–	–	32.86%	2
2023 Q1	$39.6M	Hold	5,941,120	–	–	42.23%	1
2022 Q4	$45.8M	Hold	5,941,120	–	–	48.11%	1
2022 Q3	$63.2M	Hold	5,941,120	–	–	49.97%	1
2022 Q2	$48.4M	Hold	5,941,120	–	–	39.94%	1
2022 Q1	$42.5M	Hold	5,941,120	–	–	9.03%	2
2021 Q4	$102M	Buy	+5,941,120	New	+$112M	13.74%	2

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Data Collective IV's RXRX Position: Q2 2026 in Review

Data Collective IV held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 5,941,120 shares worth $21.8M. The position accounts for 27.76% of the portfolio, ranked #3.

Data Collective IV first reported a position in RXRX in Q4 2021 and has held it in 19 quarters since. The position peaked at $102M in Q4 2021. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Data Collective IV held 5,941,120 shares of Recursion Pharmaceuticals worth $21.8M as of Q2 2026.
Data Collective IV left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
Recursion Pharmaceuticals made up 27.76% of Data Collective IV's portfolio in Q2 2026, its #3 holding.
Data Collective IV first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
Data Collective IV's Recursion Pharmaceuticals position peaked at $102M in Q4 2021.
342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Data Collective IV's 13F filing for Q2 2026, filed 14 Aug 2026.